Ceribell director Robertson sells $330k in shares

Published 20/06/2025, 17:34
Ceribell director Robertson sells $330k in shares

Director Rebecca B. Robertson of Ceribell, Inc. (CBLL), a medical technology company currently valued at $643 million, recently sold 18,633 shares of common stock for approximately $330,961. According to InvestingPro analysis, the company maintains impressive gross profit margins of 87% and holds more cash than debt on its balance sheet.

The sales occurred in two separate transactions. On June 17, 2025, Robertson sold 7,445 shares in multiple transactions at prices ranging from $17.01 to $17.90. On June 18, 2025, Robertson sold 11,188 shares in multiple transactions at prices ranging from $17.80 to $17.96. With analyst price targets ranging from $26 to $36, InvestingPro data suggests the stock is currently trading below Fair Value.

Following these transactions, Robertson directly owns 10,042 shares of Ceribell, Inc. (CBLL).

The sales were executed under a pre-arranged Rule 10b5-1 trading plan.

In other recent news, Ceribell Inc. reported a notable 42% increase in first-quarter 2025 revenue, reaching $20.5 million, despite facing a net loss of $12.8 million. The company raised its full-year revenue guidance to between $83 million and $87 million, reflecting management’s confidence in sustained growth. In addition, Ceribell received FDA clearance for a new pediatric seizure detection algorithm, expanding its market reach. At their 2025 Annual Meeting of Stockholders, Ceribell’s shareholders elected Juliet Tammenoms Bakker and Lucian Iancovici, M.D. as directors and ratified PricewaterhouseCoopers LLP as the company’s auditor for the fiscal year 2025. TD Cowen maintained a Buy rating on Ceribell, with a $36.00 price target, citing potential benefits from easing US-China trade tensions. The firm noted that Ceribell’s financial health remains strong despite tariff challenges, and any positive developments in trade discussions could improve the company’s margins. Investors are closely monitoring these developments, as they could significantly impact Ceribell’s cost structure and profitability.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.